Home » News » CROs/Service Providers » Averion Plans to Go Private

Averion Plans to Go Private

Tuesday, September 8, 2009

Averion, a contract research organization (CRO) specializing in oncology, cardiovascular diseases and medical devices, has filed a statement with the Securities and Exchange Commission (SEC) as it plans to go from a publicly traded company to one that is private.

The move will reduce the costs and administrative burdens of running a public company, Averion said, as well as allow shareholders with small holdings in the company to immediately realize the value of their investment.

Averion shareholders have approved a reverse stock split, which would give shareholders with less than 20,500 shares of common stock a cash payment of $0.01 per share. Following the transaction, the total number of shareholders will be less than 300, enabling the company to cease registration of its common stock under SEC rules.

“Averion is a successful provider of clinical research services in a very competitive business environment. The increasing cost and time associated with public company regulatory compliance required a significant amount of expense and management resources with no tangible benefit to our shareholders,” said board chairman James McGuire in a statement.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!